Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06553027
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-09
Brief Title:
To Evaluate the Efficacy of CVN424 in Parkinsons Disease Participants With Motor Complications
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study of CVN424 in Parkinsons Disease Patients With Motor Complications
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized double-blind placebo-controlled multicenter study in participants with Parkinsons disease PD with motor fluctuations Participants will be randomized to receive once-daily oral doses of either 75 milligrams mg CVN424 150 mg CVN424 or a matching placebo for 12 weeks Participants who successfully complete this study and retain eligibilitysuitability will be invited to participate in a future open-label extension OLE study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None